Your EU Sunscreen Is an OTC Drug in the USA: The Compliance Gap European Brands Can't Afford to Miss

A French skincare brand spent 18 months developing a broad-spectrum SPF 50+ sunscreen lotion. The formula cleared an EU safety assessment, passed CPNP notification without issue, and launched successfully across three EU markets. When their US distribution partner started asking about FDA compliance documentation, the conversation went sideways fast.

The problem wasn’t the safety dossier. It wasn’t label translation. It was the UV filter — a Tinosorb S-based broad-spectrum system that’s been standard in European sun care for over a decade. The US doesn’t approve it. Not for lack of data, necessarily, but because the FDA’s OTC monograph process moves at its own pace. The brand had to choose between reformulating for the US market or walking away from it entirely.

This scenario plays out more often than it should. The root cause is a fundamental regulatory category mismatch that European brands routinely underestimate.

In the EU, It’s a Cosmetic. In the USA, It Becomes a Drug.

Under EU Regulation EC No 1223/2009 — the regulation governing all cosmetic products placed on the EU market — sunscreens are cosmetics. The framework requires a cosmetic safety assessment, a Product Information File (PIF), notification through the Cosmetic Products Notification Portal (CPNP), a designated Responsible Person, and conformity with the authorized substance lists in the Regulation’s Annexes. Annex VI specifically lists the UV filter substances permitted for use in cosmetics, and includes over 25 authorized substances with defined concentration limits.

It’s a demanding framework, but the product remains a cosmetic throughout. No drug authority is involved. No pharmaceutical manufacturing audit applies.

In the United States, that same product becomes an over-the-counter (OTC) drug. The Federal Food, Drug, and Cosmetic Act (FD&C Act) classifies a product as a drug if it makes a “drug claim” — and sunscreens do. Claims like “reduces risk of sunburn,” “reduces the risk of skin cancer and early skin aging,” and even simply “sun protection factor” place a product in FDA drug territory.

The governing framework is FDA’s OTC Monograph M020, which administers sunscreen requirements under the OTC Monograph Reform Act passed as part of the CARES Act in March 2020. Before that reform, the same requirements lived in 21 CFR Part 352. The regulatory home has changed; the substance has not. Sunscreens entering the US market must comply with the monograph, full stop.

Two products. One formula. Two entirely different regulatory categories — and two entirely different compliance burdens.

The UV Filter Incompatibility Problem

This is where most European exporters hit a wall they didn’t see coming.

The FDA’s OTC sunscreen monograph covers 16 active ingredient substances. Of those 16, only two are currently classified as Category I — generally recognized as safe and effective (GRASE): zinc oxide and titanium dioxide. These are the inorganic UV blockers that have long dominated the US “clean beauty” sunscreen market.

The remaining 14 ingredients fall into one of two less favourable categories. Two — aminobenzoic acid (PABA) and trolamine salicylate — are Category II: the FDA has determined they are not GRASE. The other 12 ingredients, including octinoxate, oxybenzone, octisalate, octocrylene, avobenzone, homosalate, ensulizole, and dioxybenzone, sit in Category III. The FDA acknowledges they may be safe and effective, but has determined that insufficient data exists to make a final determination. Manufacturers using Category III actives can continue marketing them under the existing monograph framework while data requests are addressed — but the regulatory uncertainty is real, and the FDA has the authority to restrict their use through administrative order.

Now consider what’s in most high-performance European sunscreens:

• Tinosorb S (bis-ethylhexyloxyphenol methoxyphenyl triazine): outstanding broad-spectrum UVA/UVB coverage, widely used in EU SPF 50+ formulas. Not on the US monograph.
• Tinosorb M (methylene bis-benzotriazolyl tetramethylbutylphenol): photostable, effective. Not on the US monograph.
• Mexoryl XL (drometrizole trisiloxane): excellent UVA filter with photostability benefits. Not on the US monograph.
• Mexoryl SX (ecamsule): strong UVA absorber developed by L’Oréal. Received limited FDA approval via a New Drug Application for specific L’Oréal products only — not available for general monograph use.

The Sunscreen Innovation Act (2014) created a dedicated pathway for new UV filter ingredients to seek FDA approval outside the full rulemaking process. Multiple applications for European UV filters have been submitted — and have been pending review for years. As of the most recent FDA activity, none of these next-generation UV filters have been approved for broad use in US OTC sunscreen products.

The practical consequence is stark. If your EU formula relies on Tinosorb S for UVA protection, you cannot market that product in the United States without reformulation. This isn’t a labeling fix. The active ingredient itself is not on the approved list.

OTC Drug Status Means Pharmaceutical-Grade Manufacturing

Most European cosmetics manufacturers operate under ISO 22716:2007, the GMP standard developed specifically for cosmetics. ISO 22716 is a well-designed standard covering personnel, premises, equipment, raw materials, production, finished products, and documentation. It’s required for EU cosmetic compliance and it’s taken seriously by competent authorities.

But ISO 22716 is not pharmaceutical-grade GMP.

US OTC drugs must be manufactured under 21 CFR Part 211 — the FDA’s current Good Manufacturing Practice (cGMP) regulations for finished pharmaceuticals. The requirements are materially more demanding. Part 211 mandates formally validated processes, written procedures for every manufacturing step, Out-of-Specification (OOS) investigation protocols with defined timelines, rigorous equipment qualification and cleaning validation, stability testing under ICH-aligned conditions, and a documentation architecture that supports batch-level traceability to a degree that ISO 22716 doesn’t require.

Before the first US-bound shipment of a sunscreen product, the manufacturing facility must be registered with the FDA as a drug establishment under 21 CFR Part 207. The product itself must be listed with the FDA as an OTC drug — also under Part 207. Neither of these requirements exists in the EU cosmetics system. CPNP notification does not satisfy them. EU Responsible Person designation has no FDA equivalent.

US OTC sunscreen labels must also carry a Drug Facts box — a standardized label panel mandated under 21 CFR Part 201 for all OTC drug products. The Drug Facts panel specifies active ingredients and their concentrations (in a required format), directions for use, warnings (including the mandatory “keep out of reach of children” statement and the conditional skin cancer/aging risk-reduction language for SPF 15+ broad spectrum products), and inactive ingredients listed alphabetically. The EU pack layout — INCI list on the back panel, no drug facts format — doesn’t comply.

The SPF Number on Your EU Label May Not Hold Up in the US

One more layer that European brands consistently overlook: SPF testing methodology diverges between the two systems, and the same formula can generate different SPF values depending on which protocol is used.

The EU relies on ISO 24444:2010 for in vivo SPF testing and ISO 24443:2012 for in vitro UVA ratio assessment. The FDA has its own SPF testing methodology as part of the sunscreen monograph. Both systems use human subjects for in vivo SPF measurement, but the FDA method has specific protocol requirements — including precise application density and measurement timing — that differ from the ISO 24444 protocol. A product tested to ISO 24444 and labeled SPF 50 may not achieve the same numerical value under the FDA test method.

The FDA’s Broad Spectrum designation adds a further divergence. In the US, Broad Spectrum requires passing a specific in vitro critical wavelength test using a transmittance ratio method, with a required critical wavelength of at least 370 nm. Only products that pass Broad Spectrum testing and carry an SPF rating of 15 or higher may claim to reduce the risk of skin cancer and early skin aging — a claim that directly drives purchase decisions in the US market.

EU UVA compliance — whether demonstrated via PPD (persistent pigment darkening) ratio, the Boots Star Rating, or ISO 24443 in vitro methods — satisfies EU regulatory requirements but does not automatically meet the FDA Broad Spectrum standard. US-method testing must be conducted independently, using a US-approved laboratory.

How to Approach a US Sunscreen Launch as a European Brand

The roadmap isn’t short, but it is navigable once the scope is correctly understood.

Step one is always a formula audit. Map every UV filter active in your sunscreen against the FDA OTC Monograph M020 eligible ingredient list. If your formula contains any European-only UV filters, assess whether a US-compatible reformulation is viable — and what that reformulation does to your photostability profile and SPF performance.

If the formula is compatible with US-approved actives, the compliance path involves: facility registration with the FDA under 21 CFR Part 207, product drug listing, a gap assessment of your manufacturing site against 21 CFR Part 211 cGMP, a redesigned US-specific label with the Drug Facts panel, and US-method SPF and Broad Spectrum testing to support label claims. Stability data under ICH Q1A conditions should also be generated if not already available.

Realistically, a US OTC sunscreen launch done properly takes 12 to 18 months for a European brand starting from scratch — longer if manufacturing upgrades are required. Budget accordingly. The regulatory category your product lands in on the other side of the Atlantic isn’t a technicality — it’s the difference between a cosmetic file and a pharmaceutical manufacturing audit.

We work with European suncare and cosmetics brands at precisely this intersection — assessing formula compatibility with the FDA monograph, identifying US-accredited laboratory partners for OTC drug testing and SPF validation, and mapping the gap between ISO 22716 GMP and 21 CFR Part 211 manufacturing requirements.

Understanding the category before you ship is the only way to avoid the far more costly education of finding out after.

---

Written by Nour Abochama, Quality & Regulatory Advisor, Care Europe | VP Operations, Qalitex. Learn more about our team

Talk to our team about EU market entry and US FDA sunscreen compliance. Contact us

Related from our network

• OTC Drug Testing & FDA Facility Registration Support — Qalitex Laboratories provides ISO 17025-accredited OTC drug testing, SPF validation, and FDA-compliant stability studies for US market submissions.
• Sunscreen and Cosmetics Testing for the North American Market — Androxa supports brands entering both the US and Canadian markets with compliant sunscreen and topical product testing, including Health Canada Natural Health Product requirements.